Dynavax Tech Cp: (NASD: DVAX)
$2.51
0.03 (1.21%)
Volume 1,042,134
May 21 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 2.44 - 2.54 |
| 52wk Low - High | 1.74 - 5.10 |
| Previous Close | 2.48 |
| Avg. Volume | 1,532,644 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 459.03 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 2.96 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.44 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
96 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.44 |
| Current Quarter Estimate | -0.10 |
| Most Accurate Estimate | -0.10 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | -0.41 |
| Expected Earnings Growth | NA |
Company Description
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.10 | -0.11 | -0.44 | -0.43 |
| Number of Estimates | 3 | 3 | 3 | 3 |
| Low Estimate | -0.12 | -0.13 | -0.49 | -0.48 |
| High Estimate | -0.07 | -0.10 | -0.41 | NA |
| Year Ago EPS | -0.09 | -0.10 | -0.41 | -0.44 |
| EPS Growth | -11.11% | -13.33% | -6.50% | 0.76% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| DYNAVAX TECH CP | DVAX | 2.51 | |
|
| AETERNA ZENTARS | AEZS | 2.08 | |
|
| ANIKA THERAPEUT | ANIK | 14.45 | |
|
| GENTIUM SPA-ADR | GENT | 8.90 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.75 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.45 | |
|
| ALEXION PHARMA | ALXN | 102.67 | |
|
| ALKERMES INC | ALKS | 31.98 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Wider-than-Expected Loss at Dynavax
May 07, 2013
Loss at Dynavax Wider than Expected
Mar 05, 2013
Report for DVAX
May 09, 2013
Financials
| EPS TTM | -0.41 |
| Sales | 10 |
| Net Income | -74 |
| Price/Earnings | NA |
| Price/Book | 4.69 |
| Price/Cash Flow | NA |
| Price/Sales | 48.58 |
News
Dynavax Technologies Q1 net loss increases - Datamonitor
May 17, 2013
StockCall Early Morning Insight into WCRX, DVAX, ISIS, ACT, and AVNR - Accesswire-Tnw
May 15, 2013
3 Investment Strategy Lessons From Vertex`s Success - TheMotleyFool
May 11, 2013
Dynavax Technologies Corp.Corporate Event Announcement Notice - Wall Street Horizon
May 7, 2013
Dynavax Technologies appoints new CEO - Datamonitor
May 7, 2013
Dynavax Reports First Quarter 2013 Financial Results - Marketwire
May 6, 2013
Dynavax Technologies Corp.Corporate Event Announcement Notice - Wall Street Horizon
May 6, 2013
Dynavax Technologies Corp.Corporate Event Announcement Notice - Wall Street Horizon
May 4, 2013
Broker Recommendations
| Current ABR | 1.40 |
| ABR (Last Week) | 1.40 |
| # of recs in ABR | 5 |
| Average Target Price | 5.33 |
| Industry Rank by ABR | 96 out of 265 |
| Rank in Industry | 37 out of 157 |
